Maravai LifeSciences Announces Closing of Secondary Offering of Class A Common Stock by Selling Stockholders and Full Exercis...
April 12 2021 - 4:30PM
Maravai LifeSciences Holdings, Inc.
(Maravai) (NASDAQ: MRVI), a global provider of
life science reagents and services to researchers and biotech
innovators, today announced the closing of a public offering of
20,700,000 shares of Maravai’s Class A common stock by certain
selling stockholders that was previously announced, including the
full exercise of the underwriters’ option to purchase up to
2,700,000 additional shares of Class A common stock, at a price of
$31.25 per share.
Maravai did not receive any proceeds from the sale of shares by
the selling stockholders.
Morgan Stanley, Jefferies and Goldman Sachs & Co. LLC acted
as joint book-running managers for the offering. BofA Securities,
Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel
and KeyBanc Capital Markets also acted as joint book-running
managers, and Academy Securities, Loop Capital Markets, Penserra
Securities LLC and Tigress Financial Partners acted as co-managers
for the offering.
Perella Weinberg Partners L.P. served as capital markets advisor
to Maravai. Kirkland & Ellis LLP provided legal counsel to
Maravai and Davis Polk & Wardwell LLP provided legal counsel to
the underwriters.
A registration statement on Form S-1 relating to these
securities was filed with the U.S. Securities and Exchange
Commission (“SEC”) and became effective on April 7, 2021. The
offering was made only by means of a prospectus. A copy of the
final prospectus relating to the securities has been filed with the
SEC and may be obtained from: Morgan Stanley & Co. LLC, Attn:
Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY
10014; Jefferies LLC, Attention: Equity Syndicate Prospectus
Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by
telephone at 877-821-7388 or by email at
Prospectus_Department@Jefferies.com; or Goldman Sachs & Co.
LLC, Attention: Prospectus Department, 200 West Street, New York,
NY 10282, by telephone at 866-471-2526, by facsimile at
212-902-9316 or by email at prospectus-ny@ny.email.gs.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Maravai
Maravai is a leading life sciences company providing critical
products to enable the development of drug therapies, diagnostics,
novel vaccines and support research on human diseases. Maravai’s
companies are leaders in providing products and services in the
fields of nucleic acid synthesis, bioprocess impurity detection and
analysis, and protein labeling and detection to many of the world's
leading biopharmaceutical, vaccine, diagnostics, and cell and gene
therapy companies.
Contact Information:
Media Contact: Sara Michelmore
MacDougall
+1 781-235-3060
maravai@macbiocom.com
Investor Contact: Deb Hart
Maravai LifeSciences
+ 1 858-988-5917
ir@maravai.com
Maravai LifeSciences (NASDAQ:MRVI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Maravai LifeSciences (NASDAQ:MRVI)
Historical Stock Chart
From Apr 2023 to Apr 2024